We are live on ! Find out more
CLDI.WS

Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS

Delisted

CLDI.WS was delisted on the 17th of October, 2024.

Back to rankings

26 hedge funds and large institutions have $3.56M invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more capital invested

Capital invested by funds: $2.98M → $3.56M (+$577K)

0% more funds holding

Funds holding: 26 → 26 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
26
Holders Change
–
Holders Change %
0%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
6
Reduced
–
Closed
1
Calls
$4.83M
Puts
–
Net Calls
+$4.83M
Net Calls Change
-$47K

Top Buyers

Rank Fund Capital Flow
1
MF
Magnetar Financial
Illinois
+$26.2K
2
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$14.3K
3
RCM
Radcliffe Capital Management
Pennsylvania
+$3.9K
4
CAC
Cowen and Company
New York
+$2.01K
5
EFI
EHP Funds Inc
Canada
+$1.09K

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$39K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$2.61M +$3.9K +64,800 +32%
SCM
2
Segantii Capital Management
Hong Kong
$246K – – –
BFM
3
Boothbay Fund Management
New York
$223K – – –
PAMP
4
Polar Asset Management Partners
Ontario, Canada
$123K – – –
Nomura Holdings
5
Nomura Holdings
Japan
$62K – – –
Parallax Volatility Advisers
6
Parallax Volatility Advisers
California
$47K +$14.3K +238,201 +40%
FC
7
Finepoint Capital
Massachusetts
$37K – – –
6CM
8
683 Capital Management
New York
$33K – – –
SCM
9
Shaolin Capital Management
Florida
$28K – – –
AC
10
Aristeia Capital
Connecticut
$26K – – –
MF
11
Magnetar Financial
Illinois
$25K +$26.2K +435,400 New
AI
12
Arena Investors
New York
$18.9K – – –
PC
13
Periscope Capital
Ontario, Canada
$16K – – –
ICM
14
Ionic Capital Management
New York
$13K – – –
EFI
15
EHP Funds Inc
Canada
$12K +$1.09K +18,100 +9%
CAC
16
Cowen and Company
New York
$9K +$2.01K +33,400 +27%
JP Morgan Chase
17
JP Morgan Chase
New York
$8K – – –
SAMU
18
SONA Asset Management (US)
New York
$5K – – –
WAM
19
Wolverine Asset Management
Illinois
$4K – – –
AA
20
AQR Arbitrage
Connecticut
$3K – – –
PCM
21
Prelude Capital Management
New York
$3K – – –
AGM
22
Alpine Global Management
New York
$3K +$202 +3,350 +6%
Walleye Capital
23
Walleye Capital
New York
$2K +$297 +4,940 +16%
Walleye Trading
24
Walleye Trading
New York
$1K – – –
Bank of Montreal
25
Bank of Montreal
Ontario, Canada
$1 – – –
1
2

CLDI.WS Hedge Fund Activity: Q3 2022 in Review

26 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q3 2022, worth a combined $3.56M — up 19% from $2.98M a quarter earlier.

Fund positioning in CLDI.WS was balanced in Q3 2022: 1 fund opened new positions, 1 closed out, 6 added to existing stakes and 0 trimmed.

The largest buyer was Magnetar Financial, opening a new position worth an estimated $26.2K. The largest seller was Woodline Partners, exiting entirely with an estimated $39K sold.

  • 26 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $3.56M of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q3 2022, up 19% quarter-over-quarter.
  • 1 fund opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q3 2022 and 1 closed out, a net change of 0 holders.
  • The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 buyer in Q3 2022 was Magnetar Financial, an estimated $26.2K added.
  • The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q3 2022 was Woodline Partners, an estimated $39K sold.

Based on aggregated 13F filings for Q3 2022.